Asbury Rachel E, Saville Bradley A
Bioprocess and Enzyme Technology Lab, Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON, Canada.
College of Dietitians of Ontario, Toronto, ON, Canada.
Front Microbiol. 2025 Mar 24;16:1529081. doi: 10.3389/fmicb.2025.1529081. eCollection 2025.
Infections caused by pathogenic bacteria pose a significant health challenge to humans and animals, especially given the rising incidence of antimicrobial resistance. Addressing this challenge has resulted in initiatives seeking alternatives to traditional antibiotics. Manno-oligosaccharides (MOS) exhibit pathogen-binding properties, due to their ability to prevent bacterial adhesion to epithelial cells, such as those within the urinary tract and intestinal epithelium. This suggests that MOS could offer a promising alternative to antibiotics. In this study, we explore the ability of various -MOS products to inhibit the growth of and , in addition to their ability to render antibiotics more effective. Inhibition profiles were distinct for each bacterial strain and differed according to -MOS structure. Antibiotics were significantly potentiated by MOS in some cases, such as ceftazidime against . This research shows the role of carbohydrate structure in the anti-bacterial properties of non-digestible oligosaccharides such as MOS and positions MOS as a promising strategy in the treatment of bacterial infections.
致病性细菌引起的感染对人类和动物的健康构成了重大挑战,尤其是考虑到抗菌药物耐药性的日益增加。应对这一挑战促使人们采取行动寻找传统抗生素的替代品。甘露寡糖(MOS)具有病原体结合特性,因为它们能够阻止细菌粘附到上皮细胞上,如尿道和肠道上皮细胞内的细胞。这表明MOS可能是一种有前景的抗生素替代品。在本研究中,我们探究了各种MOS产品抑制粪肠球菌和金黄色葡萄球菌生长的能力,以及它们使抗生素更有效的能力。每种细菌菌株的抑制谱各不相同,并且根据MOS结构而有所差异。在某些情况下,MOS能显著增强抗生素的效果,例如头孢他啶对金黄色葡萄球菌。这项研究显示了碳水化合物结构在不可消化寡糖(如MOS)抗菌特性中的作用,并将MOS定位为治疗细菌感染的一种有前景的策略。